Antigen-specific T-cell receptor (TCR) (TCR)

The T-cell receptor (TCR) is a complex protein found on the surface of T lymphocytes that recognizes specific antigenic peptides presented by Major Histocompatibility Complex (MHC) molecules (Janeway's Immunobiology, 2001). In autoimmune diseases, autoreactive CD4+ and CD8+ T cells express TCRs that mistakenly identify self-peptides as foreign, triggering an immune attack against the body's own tissues, such as the myelin sheath in multiple sclerosis or insulin-producing cells in Type 1 diabetes (Nature Reviews Immunology, 2017). These antigen-specific TCRs are critical therapeutic targets, as modulating their activity can potentially halt disease progression without the broad side effects of systemic immunosuppression. Current therapeutic approaches include monoclonal antibodies like Teplizumab, which targets the CD3 epsilon chain associated with the TCR to induce a state of partial exhaustion or anergy in pathogenic T cells (FDA, 2022). Additionally, experimental strategies such as altered peptide ligands and MHC-peptide multimers aim to specifically target or delete only the autoreactive T-cell clones (Science Translational Medicine, 2019). Monitoring these targets often involves advanced techniques like TCR repertoire sequencing and MHC-multimer staining to track the frequency and phenotype of the autoreactive population (Frontiers in Immunology, 2020). Safety concerns primarily involve the risk of cytokine release syndrome and the potential for unintended off-target immune responses (PubMed, 2019).

Other names

T-cell receptor complexTCR-CD3 complexAlpha-beta T-cell receptorAutoreactive T-cell receptorAntigen-specific TCR

Modulation of the TCR-CD3 complex to induce immunological tolerance, T-cell anergy, or depletion of autoreactive clones.